Completed

Sandostatin's Efficacy and Safety in AIDS-Related Diarrhea Treatment

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Octreotide

Drug
Who is being recruted

Blood-Borne Infections+18

+ Urogenital Diseases

+ Genital Diseases

Over 18 Years
+2 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
See protocol details

Summary

Principal SponsorSandoz
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

This study focuses on patients with AIDS-related diarrhea who have previously participated in a study involving a drug called Sandostatin. The main goal is to understand how often the diarrhea comes back in patients who responded well to Sandostatin in the previous study. The importance of this study lies in its potential to improve the care and quality of life for patients living with AIDS-related diarrhea. In this study, patients who did not respond well to Sandostatin in the previous study will receive Sandostatin in an open-label format, meaning everyone knows they are receiving the drug. The study aims to evaluate the effectiveness and safety of Sandostatin in these patients. For those who responded well to Sandostatin in the previous study, the study will assess the effectiveness and safety of Sandostatin during a longer period of treatment.

NCT00002253
Principal SponsorSandoz
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Blood-Borne InfectionsUrogenital DiseasesGenital DiseasesCommunicable DiseasesImmunologic Deficiency SyndromesImmune System DiseasesInfectionsRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted DiseasesSigns and SymptomsSigns and Symptoms, DigestiveSlow Virus DiseasesPathological Conditions, Signs and SymptomsVirus DiseasesSexually Transmitted Diseases, ViralLentivirus InfectionsAcquired Immunodeficiency SyndromeAIDS-Related ComplexDiarrheaHIV Infections

Criteria

2 inclusion criteria required to participate
Each of these patients must give written informed consent to participate in Study D204, FDA 102B as well.
Only patients who have completed the duration of Study D203, FDA 102A will be eligible for this study.

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 22 locations

USC School of Medicine

Los Angeles, United StatesOpen USC School of Medicine in Google Maps

UCSD Med Ctr

San Diego, United States

UCSF - San Francisco Gen Hosp

San Francisco, United States

Kaiser Permanente Med Ctr

San Francisco, United States
Completed22 Study Centers